Bailón, Lucia http://orcid.org/0000-0001-7277-9314
Llano, Anuska http://orcid.org/0000-0002-0133-9888
Cedeño, Samandhy http://orcid.org/0000-0001-8312-0208
Escribà, Tuixent http://orcid.org/0000-0001-9467-7802
Rosás-Umbert, Miriam http://orcid.org/0000-0002-2850-6586
Parera, Mariona
Casadellà, Maria http://orcid.org/0000-0002-4115-2305
Lopez, Miriam
Pérez, Francisco
Oriol-Tordera, Bruna http://orcid.org/0000-0002-2714-9097
Ruiz-Riol, Marta
Coll, Josep
Perez, Felix
Rivero, Àngel
Leselbaum, Anne R.
McGowan, Ian http://orcid.org/0000-0002-6470-8476
Sengupta, Devi
Wee, Edmund G.
Hanke, Tomáš http://orcid.org/0000-0002-6076-9546
Paredes, Roger http://orcid.org/0000-0002-6553-691X
Alarcón-Soto, Yovaninna http://orcid.org/0000-0002-9977-8634
Clotet, Bonaventura http://orcid.org/0000-0003-3232-4598
Noguera-Julian, Marc http://orcid.org/0000-0002-6194-1395
Brander, Christian http://orcid.org/0000-0002-0548-5778
Molto, Jose
Mothe, Beatriz http://orcid.org/0000-0001-9975-407X
Barriocanal, Ana María
Benet, Susana
Cobarsi, Patricia
Geleziunas, Romas
Leselbaum, Anne R.
Loste, Cora
Meulbroek, Michael
Miranda, Cristina
Muñoz, Jose
Naval, Jordi
Nieto, Aroa
Pujol, Ferran
Puig, Jordi
,
Article History
Received: 3 November 2021
Accepted: 28 September 2022
First Online: 27 October 2022
Competing interests
: C.B., B.M. and A.L.L. are co-inventors of the HTI immunogen (patent application PCT/EP2013/051596). C.B., B.M. and I.M. are co-inventors of US patent application no. 62/935,519 and US patent application no. 62/851,546, which have relevance to the vaccine regimen used in this study. B.M. reports consultancy personal fees from AELIX Therapeutics SL, as well as speakers’ fees from Gilead, Janssen and ViiV Healthcare, outside the submitted work. C.B. is co-founder, CSO and shareholder of AELIX Therapeutics SL and serves as an advisor for Tendel Therapies and OmniScope, outside the submitted work. M.N.-J. is co-founder and shareholder of Nano1Health SL, outside the scope of the submitted work. I.M. is a shareholder of, and acts as a consultant to, AELIX Therapeutics SL. He is also the CMO of Orion Biotechnology, outside the scope of the submitted work. J.M. has received research funding, consultancy fees and lecture sponsorships from, and has served on advisory boards for, various laboratories (MSD, Abbvie, Boehringer Ingelheim, Gilead Sciences, Viiv Healthcare, Janssen-Cilag and Bristol-Myers-Squibb). The remaining authors declare no competing interests.
Free to read: This content has been made available to all.